A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib inPatients with Metastatic Triple Negative Breast Cancer

Contact:

NCT Number:

Protocol:

AAAT5795

Study Status:

Closed to Accrual, Study Active

Population:

Adult

Phase:

I/II

This study is being done to answer the following question: How does the combination of copanlisib and eribulin compare to eribulin alone to lengthen the time you can live with your metastatic triple negative breast cancer without your cancer getting worse? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your triple negative breast cancer. The usual approach is defined as care most people get for metastatic TNBC.

Are you Eligible? (Inclusion Criteria)

  • Are you 18 years of age or older?
  • Do you have metastatic or unresectable Triple-Negative Breast Cancer?
  • Are you able to make extra visits to the clinic for treatment and evaluations?

Specialty Area(s)

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032